The United States of America, As Represented by the Secretary, Department of Health and Human Services

Maria R Parkhurst

Steven A Rosenberg

Richard A Morgan

Patrick Hwu

Rejean LaPointe

Shannon Faith Rosati

Anna Pasetto

Rami Yoseph

Paul F Robbins

Yong-Chen Lu

Richard Arthur Morgan

Drew C Deniger

Parisa Malekzadeh

Winifred M Lo

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

HLA class II-restricted t cell receptors against RAS with G12R mutation

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

T cell receptors recognizing mutated P53

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.

Murine anti-NY-ESO-1 T cell receptors

Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.

Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods

Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods

Growing community of inventors

Ellicott City, MD, United States of America

Maria R Parkhurst